All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-PD-L1 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human PD-L1. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-PD-L1 antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of B-cell malignancies.
CAR Construction : Fig.1 DLD-1 cells were treated with or without 20 ng/mL IFNg in the presence or absence of 8 mg/mL IFN-y neutralizing mAb. IFNg upregulates PD-L1 expression and sensitizes cancer cells to TRAIL-mediated apoptosis. Hendriks, D., He, Y., Koopmans, I., Wiersma, V. R., van Ginkel, R. J., Samplonius, D. F., ... & Bremer, E. (2016). Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction. Oncoimmunology, 5(8), e1202390. |
CAR Construction : Fig.2 PD-L1xCSPG4 simultaneously binds to CSPG4 on one cell type and PD-L1 on a nearby other cell type forming cell clusters. Construction and production of PD-L1xCSPG4. Koopmans, I., Hendriks, M. A., van Ginkel, R. J., Samplonius, D. F., Bremer, E., & Helfrich, W. (2019). Bispecific antibody approach for improved melanoma-selective PD-L1 immune checkpoint blockade. Journal of Investigative Dermatology, 139(11), 2343-2351. |
CAR Construction : Fig.3 Binding of PD-L1xEGFR vs. PD-L1xMock (5 mg/ml) to a series of PD-L1xEGFRC and PD-L1xEGFR cell lines. Statistical analysis in D was performed using One-way ANOVA followed by a Bonferroni post-hoc test. Koopmans, I., Hendriks, D., Samplonius, D. F., van Ginkel, R. J., Heskamp, S., Wierstra, P. J., ... & Helfrich, W. (2018). A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. Oncoimmunology, 7(8), e1466016. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-PD-L1 (3G10) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-ZP264). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION